Most sales teams selling into pharma, biotech, and medtech are chasing the same lagging indicators. A clinical trial hits ClinicalTrials.gov and everyone pounces. A press release announces a platform decision and reps start cold-calling. By then, the vendor shortlist was locked weeks ago. The teams that consistently win life sciences deals are tracking different life sciences deal signals, ones that fire months before the formal buying process begins.
6sense's 2025 Buyer Experience Report found that 81% of B2B buyers have already chosen their preferred vendor before they ever talk to sales. In life sciences, where procurement cycles are longer and compliance requirements narrow the field, that number is likely higher. If you are not on the shortlist before the formal evaluation begins, you are not in the deal.
The question is not whether to track buying signals. It is which signals actually predict tech spend before the procurement process starts. After watching patterns across hundreds of life sciences accounts, three deal signals consistently fire months before budget gets allocated.
TL;DR: Life sciences deals begin long before the RFP. Three signals predict upcoming tech spend with high reliability: regulatory filing surges (IND/NDA activity), new CRO/CMO partnerships, and VP-level data or technology hires. Salesmotion monitors all three automatically across your entire territory, so reps can engage accounts during the procurement window instead of after it closes.
Life Sciences Deals Don't Start With an RFP
The life sciences buying cycle is fundamentally different from other B2B verticals. A pharma company does not wake up one morning and decide to buy a new analytics platform. The buying process begins with an operational trigger: a regulatory milestone, a partnership that changes the technology requirements, or a new leader who arrives with a mandate to modernize.
Biopharma giants have committed more than $480 billion toward manufacturing and R&D projects as of late 2025. Over 40% of big pharma revenue faces patent expiration risk in the next six years, driving a wave of M&A, outsourcing deals, and technology investments. That spending does not flow evenly. It flows in bursts, triggered by specific events that sales teams can track if they know what to watch.
According to ZS's 2025 pharma industry survey, 93% of pharma and biotech executives plan to increase spending on data, digital, and AI. Clinical development and R&D are expected to receive the largest share of that investment. For sales teams, this means the accounts are spending. The question is whether you are engaged before the budget is committed or after.
The three signals below are the ones that most consistently predict when that spending is about to happen.
See Salesmotion on a real account
Book a 15-minute demo and see how your team saves hours on account research.
Signal 1: Regulatory Filing Surges
When a company files an IND (Investigational New Drug) application or submits an NDA (New Drug Application), a procurement window opens. The FDA receives approximately 1,500 new INDs per year. Each one represents a company that is about to scale clinical operations, and clinical operations require technology.
An IND filing signals that a sponsor is transitioning from preclinical to clinical. They need clinical trial management systems, data platforms, regulatory compliance tools, and often new CRO partnerships. The technology procurement decisions typically happen within 90 days of the filing, before the trial protocol is finalized and long before anything shows up on ClinicalTrials.gov.
NDA submissions create a different but equally valuable window. A company submitting an NDA is preparing for commercial launch. That means scaling manufacturing, building market access teams, and investing in commercial analytics. Each of these creates vendor evaluation cycles.
Where to find this signal: FDA databases, SEC filings (companies disclose material regulatory milestones), and ClinicalTrials.gov for trial status changes.
The problem for most sales teams: Monitoring FDA databases manually across a territory of 50 to 200 accounts is not realistic. By the time a rep spots the filing on a news aggregator, the 90-day window may already be closing.
An account intelligence platform that tracks regulatory filings, SEC disclosures, and clinical trial updates automatically changes this dynamic. When an IND filing or NDA submission hits, the account brief updates with the regulatory context alongside related signals like hiring activity and earnings commentary. Reps see the full picture, not an isolated data point.
“The AI templates were a surprise delight. We expected the data, but the pre-built email suggestions turned out to be much better than expected and a huge help, especially for newer reps.”
Sabina Malochleb-Bazaud
Senior Sales Operations Administrator, Cytel
Signal 2: CRO/CMO Partnership Announcements
The biopharmaceutical CRO and CMO market reached $83 billion in 2025 and is growing at 6.7% annually. Every new outsourcing contract between a pharma sponsor and a CRO or CMO represents a company that is scaling a program and building a new vendor stack.
When a biotech announces a partnership with a contract research organization, it means they are moving a program forward. They need the supporting technology: electronic data capture, pharmacovigilance platforms, supply chain tools, and analytics. The vendor evaluation window for these supporting tools is typically 60 days from the partnership announcement, before internal IT gets fully involved and budgets get locked.
This signal is particularly valuable because it is public. CRO partnership announcements appear in press releases, LinkedIn posts from executives, and industry publications like BioPharma Dive. But manually scanning these sources across dozens of accounts is exactly the kind of work that falls off a rep's plate on a busy Tuesday.
A concrete example: A mid-sized biotech announces a Phase III partnership with a top-10 CRO. Within days, LinkedIn shows the company hiring clinical data managers and regulatory affairs specialists. The earnings call from the previous quarter mentioned "accelerating our late-stage pipeline." These signals together point to a company that will be evaluating technology vendors within weeks.
The right platform consolidates these signals into a single account view. The CRO partnership announcement, the hiring activity, and the earnings call language all appear in one brief. A rep preparing for outreach can reference the specific partnership and the hiring pattern in their message, instead of sending a generic "I'd love to show you our platform" email.
Signal 3: New VP of Data or Technology Leader
When a pharma or biotech company hires a new VP of Data, Head of Clinical Informatics, or Chief Digital Officer, someone with budget and a mandate just walked in the door. New technology leaders are building their vendor list in their first 30 days. They are evaluating existing tools, identifying gaps, and meeting potential partners. If you are not in front of them during that window, you are competing against incumbents who had a head start.
This signal is the most reliable predictor of modernization spend. A company does not hire a VP of Data to maintain the status quo. They hire that person to change something: consolidate fragmented data platforms, implement AI capabilities, or upgrade clinical trial technology. ZS's survey data confirms this. Nearly half of pharma tech leaders expect their data and AI investments to drive measurable value in 2026. Someone has to select and implement those tools.
The 90-day mandate: New executives typically have a 90-day window to demonstrate early wins. During those first three months, they are most open to meeting new vendors, most willing to evaluate alternatives to legacy systems, and most motivated to make decisions quickly. After the first quarter, the strategy is set, the vendor shortlist is finalized, and new entrants face an uphill battle.
Where to find this signal: LinkedIn hiring announcements, job postings (a VP of Data hire often follows a wave of data engineering job posts), and executive announcements in industry publications.
Automated signal monitoring changes this. When a new technology or data leader joins a target account, the platform flags the change, surfaces the executive's background, and connects it to other account signals like recent funding or regulatory activity. Instead of discovering the hire three months later on LinkedIn, reps know within days.
“All of the vendors that I've worked with, all of the onboarding that I have had to deal with, I will say, hands down, Salesmotion was the easiest that I have had.”
Lyndsay Thomson
Head of Sales Operations, Cytel
How Salesmotion Surfaces These Signals Automatically
Tracking IND filings, CRO partnerships, and leadership hires across a territory of 100+ life sciences accounts is not a manual task. It is a monitoring system.
Here is how the workflow looks in practice:
Trigger: A target biotech account files an IND for a new therapeutic candidate. The same week, LinkedIn shows the company posted three clinical data management roles.
Platform action: Salesmotion's Signal Agent flags the account with the regulatory filing and the hiring surge. The account brief auto-updates with context: the filing details, the related job postings, and a note from the previous quarter's earnings call where leadership mentioned "expanding our Phase II pipeline."
Rep action: The rep opens the account brief and sees the full picture in under five minutes. Instead of spending an hour toggling between FDA.gov, LinkedIn, and the company's investor relations page, they have the context they need to write a relevant, timely outreach message.
Outcome: The rep reaches the account during the procurement window, before the vendor shortlist is finalized. The message references the specific IND filing and the clinical hiring pattern. The prospect responds because the outreach demonstrates that the rep understands their business, not because it was a well-timed template.
This is the pattern that life sciences teams at companies like Cytel use daily. Cytel's sales team consolidated five research tools into Salesmotion and cut account research time by 50%, with 30% faster account planning. For a team covering hundreds of pharma and biotech accounts, that time savings translates directly into more accounts covered and more procurement windows caught.
Key Takeaways
- Life sciences deals begin with operational triggers (regulatory filings, CRO partnerships, executive hires), not RFPs. Sales teams that wait for formal procurement miss the window.
- IND and NDA filings create a 90-day procurement window for clinical and commercial technology. Monitor FDA databases and SEC disclosures to catch them early.
- New CRO/CMO partnerships signal a company building a new vendor stack. The 60-day window before IT involvement is when technology decisions are most fluid.
- VP-level data and technology hires come with a 90-day mandate to modernize. New leaders build vendor lists in their first month.
- Monitoring these signals manually across 100+ accounts is not sustainable. Automated signal detection across regulatory, hiring, partnership, and earnings data is the only way to cover an entire territory.
- Cytel's life sciences sales team cut research time by 50% and account planning by 30% after consolidating five research tools into Salesmotion.
Frequently Asked Questions
How early do life sciences procurement decisions happen before an RFP?
Most technology procurement decisions in life sciences begin 3 to 6 months before a formal RFP or vendor evaluation process. The trigger is typically an operational event like an IND filing, a CRO partnership, or a new technology leader joining the company. By the time the RFP is issued, the shortlist of 3 to 4 vendors has usually been established through informal conversations and referrals during the signal window.
What makes life sciences buying signals different from other B2B verticals?
Life sciences buying signals are tied to regulatory and clinical milestones that are unique to the industry. FDA filings, clinical trial phase transitions, CRO partnerships, and patent expiration timelines all create predictable procurement windows. Unlike general B2B intent signals (website visits, content downloads), these regulatory and operational signals are public, verifiable, and directly connected to budget allocation decisions.
How do account intelligence platforms track FDA filings and regulatory signals?
Platforms like Salesmotion monitor over 1,000 public and private sources, including FDA databases, SEC filings, ClinicalTrials.gov, press releases, earnings call transcripts, and job postings. When a regulatory event (IND filing, NDA submission, FDA approval) occurs for a target account, the platform flags the signal, updates the account brief with context, and alerts the assigned rep. This happens automatically across the entire territory without manual monitoring.
How do CRO sales teams track sponsor buying behavior at scale?
CRO sales teams monitor pharma and biotech sponsors for signals that indicate upcoming outsourcing decisions: new funding rounds, clinical pipeline expansions, executive hires in clinical operations, and earnings call language about development timelines. Life sciences companies like Cytel use automated account intelligence to consolidate what previously required five separate research tools into one system, cutting research time by 50%.
